Bone and soft-tissue sarcoma: Preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging

Radiology

Volumn 245, Issue 3, 2007, Pages 839-847

  Tateishi, Ukihide ^a,c   Yamaguchi, Umio ^a   Seki, Kunihiko ^a   Terauchi, Takashi ^b   Arai, Yasuaki ^a   Kim, E Edmund ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; IOPAMIDOL; OXIDRONATE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE CANCER; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; CHILD; CHONDROSARCOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EWING SARCOMA; FEMALE; HISTOLOGY; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; SCINTILLATION CAMERA; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36248971814     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2453061538     Document Type: Article

References (23)

1. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-261.
2. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215-1220.
3. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-1287.
4. Reuther G, Mutschler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol 1990;19:85-90.
5. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using F-18 fluorodeoxyglucose. Ann Surg Oncol 1997;4:57-63.
6. Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998;80:441-447.
7. Johnson GR, Zhuang H, Khan J, et al. Role of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med 2003;28:815-820.
8. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with F-18 fluoro-2-deoxy-d-glucose. Radiology 1992;182:185-194.
9. Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999;86:550-556.
10. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380-386.
11. Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717-724.
12. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
13. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
15. Green FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer, 2002.
16. Sobin LH, Wittekind C. UICC TNM classification of malignant tumours. 6th ed. New York, NY: Wiley, 2002.
17. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305-1311.
18. Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001;12:479-486.
19. Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002;13:137-160.
20. Daldrup-Link HE, Franzius C, Rummeney EJ, et al. Whole body MRI for detection of bone marrow metastases in pediatric patients: comparison with skeletal scintigraphy and FDG-PET. AJR Am J Roentgenol 2001;177:229-236.
21. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol 1997;169:1675-1680.
22. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26:308-314.
23. Tateishi U, Hasegawa T, Yamamoto S, et al. Incidence of multiple primary malignancies in a cohort of adult patients with soft tissue sarcoma. Jpn J Clin Oncol 2005;35:444-452.